Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus termed SARS-CoV. We have previously shown that SARS-CoV has the ability to prevent the activation of IRF-3, thus inhibiting the synthesis of the antiviral type I interferons (IFN) such as IFN-beta. Several unspecific as well as IRF-3-specific IFN antagonists of SARS-CoV have recently been identified. However it was also suggested that cells may simply be unable to detect the infection, because the virus is hiding in compartments surrounded by a double layer of membranes. Here, we demonstrate that this balance of viral hiding and preventing the activation of the cellular defense mechanisms can be tipped by pretreating cells with small amounts of IFN-alpha. By exploiting this priming effect, we were able to achieve an induction of IFN-beta and several other antiviral genes in response to infection with SARS-CoV. Surprisingly however, neither IFN nor other cytokines were secreted into the supernatant, although the corresponding mRNAs were clearly upregulated, whereas expression of endogenous proteins remained unaffected. These findings indicate that SARS-CoV does also inhibit a step following transcription of antiviral genes, most probably by inhibiting the secretion of cellular proteins. Thus, SARS-CoV displays a wide range of measures to counteract the type I IFN response at multiple levels.
